10.03USD+0.85%Mkt Cap: 191.62M USDP/E: —Last update: 2026-05-26
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap191.62M USD
Enterprise Value188.34M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.57M USD
Revenue/Share—
Last Price10.03 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.63
PEG—
EV/EBITDA-5.04
EV/Revenue—
P/S—
P/B-128.57
EPS (TTM)-2.36
EPS (Forward)-1.76
52W Range
5.24049% of range14.93
52W High14.93 USD
52W Low5.240 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-2418.77%
ROA-153.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.95M USD
CapEx (TTM)16.00K USD
FCF Margin—
FCF Yield-12.26%
Net Debt-608.00K USD
Net Debt/EBITDA0.02
Balance Sheet
Debt/Equity8.87
Current Ratio2.24
Quick Ratio2.07
Book Value/Sh-0.0770 USD
Cash/Share0.7830 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 2, 2023
Analyst Consensus
Rating—
Target (Mean)17.50 USD
Target Range17.00 USD – 18.00 USD
# Analysts2
Ownership
Shares Out.19.09M
Float13.19M
Insiders29.76%
Institutions16.99%
Short Interest
Short Ratio13.2d
Short % Float12.93%
Short % Out.8.86%
Shares Short1.66M
Short (prev mo.)1.31M
Technical
SMA 5010.97 (-8.5%)
SMA 2009.908 (+1.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)138.34K
Avg Vol (10d)158.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—